tradingkey.logo
搜索

诺华制药

NVS
添加自选
154.440USD
-1.700-1.09%
收盘 07-23 16:00美东报价延迟15分钟
293.55B总市值
21.98市盈率 TTM

关于 诺华制药 公司

诺华公司为瑞士总部的全球制药巨头,专注创新处方药的研发、制造与行销。公司现以单一 创新药物 部门运营,聚焦免疫、肿瘤、神经、心血管、肾脏及代谢等治疗领域,并运用数字平台加速临床与商业决策。此前属下的仿制药与生物仿制药业务已分拆为独立公司 Sandoz,因此诺华资源得以全面投入先进疗法与下一代技术平台。

诺华制药简介

公司代码NVS
公司名称Novartis AG
上市日期May 07, 2001
CEONarasimhan (Vasant)
员工数量75883
证券类型Depository Receipt
年结日May 07
公司地址Lichtstrasse 35
城市BASEL
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家Switzerland
邮编4056
电话41613241111
网址https://www.novartis.com/
公司代码NVS
上市日期May 07, 2001
CEONarasimhan (Vasant)

诺华制药公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Harry Kirsch
Mr. Harry Kirsch
Chief Financial Officer, Member of the Executive Committee
Chief Financial Officer, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Vasant (Vas) Narasimhan, M.D.
Dr. Vasant (Vas) Narasimhan, M.D.
Chief Executive Officer, Member of the Executive Committee
Chief Executive Officer, Member of the Executive Committee
--
--
Mr. Frans van Houten
Mr. Frans van Houten
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Steffen Lang, Ph.D.
Dr. Steffen Lang, Ph.D.
President - Operations, Member of the Executive Committee
President - Operations, Member of the Executive Committee
--
--
Mr. Patrice Bula
Mr. Patrice Bula
Non-Executive Lead Independent Director
Non-Executive Lead Independent Director
--
--
Ms. Bridgette P. Heller
Ms. Bridgette P. Heller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Harry Kirsch
Mr. Harry Kirsch
Chief Financial Officer, Member of the Executive Committee
Chief Financial Officer, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Vasant (Vas) Narasimhan, M.D.
Dr. Vasant (Vas) Narasimhan, M.D.
Chief Executive Officer, Member of the Executive Committee
Chief Executive Officer, Member of the Executive Committee
--
--

常见问题

诺华制药的前五大股东是谁?

诺华制药 的前五大股东如下:Mr. Harry Kirsch

有多少机构持有诺华制药(NVS)的股份?

截至2026Q1,共有2164家机构持有诺华制药的股份,合计持有的股份价值约为143.01M,占公司总股份的7.49%。与2025Q4相比,机构持股有所增加,增幅为-1630148.00。

哪个业务部门对诺华制药的收入贡献最大?

在2026Q1,Rest of portfolio业务部门对诺华制药的收入贡献最大,创收10.02B,占总收入的18.37%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有